Description

BSE announces Demat Auction for Settlement No. 826 dated February 24, 2026, listing 87 scrips with quantities to be auctioned across various sectors.

Summary

Bombay Stock Exchange Ltd. (BSE), Mumbai has announced a Demat Auction for Settlement No. 826, dated February 24, 2026. The notice lists 87 scrip entries (across approximately 85 unique companies) with the quantities of shares to be auctioned in the demat segment.

Key Points

  • Settlement No. 826 demat auction conducted on February 24, 2026
  • 87 scrip entries covering a wide range of sectors including banking, pharma, energy, infrastructure, and consumer goods
  • Largest auction quantities include: DEE DEVELOPM (25,638 shares), Blue Jet Healthcare (10,686 shares), GUJARAT TOOL (13,598 shares), R M DRIP AND (5,136 shares), and ANUPAM FINSE (1,697 shares)
  • Auction covers well-known large-cap names such as Axis Bank, AU Small Finance Bank, Sun Pharma, Tata Motors, Ola Electric, GMR Airports, Suzlon Energy, and Muthoot Finance
  • Also includes several SME and mid-cap scrips

Regulatory Changes

No regulatory changes. This is a routine operational notice for the conduct of a scheduled demat auction.

Compliance Requirements

  • Brokers and trading members whose clients have shortfalls in the specified scrips should take note of the auction quantities
  • Settlement obligations for the listed scrips must be fulfilled through the auction process per standard BSE settlement rules

Important Dates

  • Auction Date: February 24, 2026
  • Settlement Number: 826

Impact Assessment

This is a routine demat auction notice with low market impact. The quantities involved for most scrips are small relative to typical daily trading volumes. Participants with outstanding settlement obligations in any of the listed 87 scrip entries should review their positions. The auction affects a diverse cross-section of equities but does not signal any systemic or sector-wide concern.

Impact Justification

Routine demat auction notice for a single settlement; affects a broad but specific set of scrips with relatively small quantities; no regulatory changes or compliance obligations for general market participants.